Pancreatic Cancer Research

ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteActive in the last 2 years

Mark Bloomston

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2987-947X; OpenAlex author ID A5039174329. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 3, last author 5)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
2
Collaborators
62
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: 1 paper, 1 trial · 2012: 2 papers · 2013: 6 papers · 2014: 4 papers · 2015: 3 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 20

  1. Lifetime stressor exposure and depression among patients with pancreatic cancer: insights from the Florida Pancreas Collaborative. Co-author DOI 10.1186/s12885-025-15007-w↗
  2. Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for Borderline Resectable Pancreatic Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-5183420/v1↗
  3. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
  4. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311585↗
  5. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Last author DOI 10.1007/s00262-015-1679-3↗
  6. Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer Co-author DOI 10.1186/2051-1426-3-s2-p366↗
  7. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Co-author DOI 10.18632/oncotarget.6332↗
  8. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Co-author DOI 10.1093/carcin/bgu124↗
  9. Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: a review. First author DOI 10.1155/2014/468959↗
  10. BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer Co-author DOI 10.1186/2051-1426-2-s3-p186↗
  11. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Last author DOI 10.1245/s10434-013-3240-y↗
  12. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.28117↗
  13. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. Last author DOI 10.1016/j.jss.2013.04.061↗
  14. Therapeutic endoscopic ultrasonography: intratumoral injection for pancreatic adenocarcinoma. Co-author DOI 10.1155/2013/207129↗
  15. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Co-author DOI 10.1158/0008-5472.can-12-4601↗
  16. Genetically engineered murine pancreatic cancer models approximate immunophenotypic properties of human patients Co-author DOI 10.1186/2051-1426-1-s1-p163↗
  17. Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment. First author DOI 10.4161/onci.24891↗
  18. Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Last author DOI 10.1245/s10434-012-2337-z↗
  19. The spectrum of hematologic malignancies involving the pancreas: potential clinical mimics of pancreatic adenocarcinoma. First author DOI 10.1309/ajcpcxw7qug9efto↗
  20. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Last author DOI 10.1245/s10434-010-1397-1↗

Trials 2

  1. Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery Principal investigator NCT01646697↗
  2. AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) Principal investigator NCT00638612↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gregory B. Lesinski · 10 shared papers, 2013–2019 · strength 0.48
  2. Tanios Bekaii‐Saab · 11 shared papers, 2011–2019 · strength 0.47
  3. Thomas A. Mace · 9 shared papers, 2013–2019 · strength 0.43
  4. Wendy L. Frankel · 6 shared papers, 2012–2014 · strength 0.23
  5. Thomas Ludwig · 5 shared papers, 2013–2018 · strength 0.22
  6. W. Garrett Nichols · 1 shared paper, 2024 · strength 0.22
  7. Paul Peter Tak · 1 shared paper, 2024 · strength 0.22
  8. Fidel David Huitzil Melendez · 1 shared paper, 2024 · strength 0.22
  9. Daniel K. Jeong · 1 shared paper, 2025 · strength 0.19
  10. Anthony DeSomma · 1 shared paper, 2025 · strength 0.19
  11. Kun Jiang · 1 shared paper, 2025 · strength 0.19
  12. Dae Won Kim · 1 shared paper, 2025 · strength 0.19
  13. José M. Pimiento · 1 shared paper, 2025 · strength 0.19
  14. Vic Velanovich · 1 shared paper, 2025 · strength 0.19
  15. Margaret A. Park · 1 shared paper, 2025 · strength 0.19
  16. Jennifer B. Permuth · 1 shared paper, 2025 · strength 0.19
  17. Michael C. Ostrowski · 4 shared papers, 2013–2018 · strength 0.19
  18. Amy Collins · 4 shared papers, 2012–2014 · strength 0.16
  19. Jason Robert Pitarresi · 3 shared papers, 2015–2018 · strength 0.15
  20. Zobeida Cruz‐Monserrate · 2 shared papers, 2018–2019 · strength 0.14
  21. Lawrence A. Shirley · 3 shared papers, 2013–2015 · strength 0.13
  22. Peter Muscarella Md · 3 shared papers, 2011–2014 · strength 0.12
  23. Xiaoling Zhong · 2 shared papers, 2015–2018 · strength 0.11
  24. Teresa A Zimmers · 2 shared papers, 2015–2018 · strength 0.11
  25. Lianbo Yu · 2 shared papers, 2014–2018 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.